Effects of glyburide therapy on lipoproteins in non-insulin-dependent diabetes mellitus.

Abstract

Twenty-seven patients with non-insulin-dependent diabetes mellitus and fasting plasma glucose values greater than 140 mg/dl began glyburide therapy. After entry into the study, patients were classified into three phenotypes on the basis of their initial lipoprotein profile: type IV, mixed, and normal. Glyburide lowered plasma glucose and raised plasma insulin concentrations in non-insulin-dependent diabetes mellitus. Patients with type IV hyperlipoproteinemia had higher fasting free insulin concentrations before and after therapy than patients without hyperlipoproteinemia and may have a slightly reduced hypoglycemic response to glyburide therapy. The drug caused a significant reduction in very-low-density lipoprotein cholesterol in patients with non-insulin-dependent diabetes mellitus and type IV hyperlipoproteinemia, along with a variable change in high-density lipoprotein cholesterol, independent of its effect on plasma glucose.

• Authors: T A Hughes, J O Kramer, J P Segrest
• Journal: The American journal of medicine (Am J Med) Vol. 79 Issue 3B Pg. 86-91 (Sep 20 1985) ISSN: 0002-9343 [Print] United States
• PMID: 3931466 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cholesterol, VLDL
• Insulin
• Lipoproteins
• Lipoproteins, VLDL
• Cholesterol
• Glyburide

Topics

• Cholesterol (metabolism)
• Cholesterol, VLDL
• Diabetes Mellitus, Type 2 (drug therapy)
• Evaluation Studies as Topic
• Glyburide (therapeutic use)
• Humans
• Insulin (therapeutic use)
• Lipoproteins (metabolism)
• Lipoproteins, VLDL (metabolism)
• Obesity (complications)